Tonghua Dongbao Pharmaceutical

About:

Tonghua Dongbao Pharma develops and markets recombinant human insulin for the treatment of diabetes.

Website: http://www.thdb.com/

Top Investors: DCP Capital

Description:

Tonghua Dongbao Pharma develops and markets recombinant human insulin for the treatment of diabetes.

Total Funding Amount:

$283M

Headquarters Location:

Tonghua, Shanxi, China

Founded Date:

1985-01-01

Founders:

Number of Employees:

251-500

Last Funding Date:

2020-09-10

IPO Status:

Public

Industries: